Payers should collaborate with plan sponsors, PBMs, manufacturers and providers to expand GLP-1 coverage: Payers have a key role in realizing GLP-1 cost savings as well as ensuring equitable, affordable access and quality of care by collaborating with PBMs, GLP-1 manufacturers and plan sponsors to expand GLP-1 coverage while driving down costs
10.1038/s41419-018-0635-5 143 MengX.-M.LiH.-D.WuW.-F.Ming-Kuen TangP.RenG.-L.GaoL.et al (2018)
The Recover IV delivers amino acids, B vitamins, and electrolytes directly into the bloodstream, supporting faster muscle repair and reducing the inflammatory response associated with strenuous exertion
Generic alternatives reduce this to $20-35 CAD for equivalent amounts, making monthly costs approximately $7-20 CAD depending on brand preference
In some research contexts, observations have included mild and transient tolerability-related effects such as: Headaches Nausea Stimulation-related observations Temporary injection-site irritation or localized skin-response variability Research conditions, concentration ranges, dosage ranges, hydration status, administration frequency, and protocol structure may influence tolerability observations across experimental settings
